LGND

111.67

0.04% -0.04

Handel nachbörslich: 111.67

Ligand Pharmaceuticals Inc (LGND)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$111.71

Offen:

$110.87

24-Stunden-Volumen:

124.18K

Relative Volume:

1.17

Marktkapitalisierung:

$2.11B

Einnahmen:

$118.31M

Nettoeinkommen (Verlust:

$96.34M

KGV:

77.55

EPS:

1.44

Netto-Cashflow:

$-19.62M

1W Leistung:

-9.56%

1M Leistung:

+4.96%

6M Leistung:

+29.76%

1J Leistung:

+93.13%

1-Tages-Spanne:

$109.44

$113.04

1-Wochen-Bereich:

$109.44

$125.76

52-Wochen-Spanne:

$57.00

$129.90

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Firmenname

Ligand Pharmaceuticals Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

858-550-7500

Adresse

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Mitarbeiter

Twitter

@Ligand_LGND

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

LGND's Discussions on Twitter

Vergleichen Sie LGND mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LGND	111.67	2.11B	118.31M	96.34M	-19.62M	1.44
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-04-14	Fortgesetzt	Stephens	Overweight
2021-02-04	Bestätigt	H.C. Wainwright	Buy
2020-10-06	Eingeleitet	Barclays	Overweight
2020-03-24	Herabstufung	Argus	Buy → Hold
2020-03-10	Eingeleitet	Guggenheim	Neutral
2020-02-06	Eingeleitet	The Benchmark Company	Buy
2019-09-19	Hochstufung	Barclays	Equal Weight → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-03	Bestätigt	H.C. Wainwright	Buy
2019-03-06	Bestätigt	H.C. Wainwright	Buy
2018-10-29	Hochstufung	ROTH Capital	Neutral → Buy
2018-10-02	Bestätigt	H.C. Wainwright	Buy
2018-09-11	Bestätigt	Argus	Buy
2018-08-17	Eingeleitet	Goldman	Neutral
2018-08-08	Herabstufung	ROTH Capital	Buy → Neutral
2018-06-21	Eingeleitet	Argus	Buy
2017-12-27	Bestätigt	H.C. Wainwright	Buy
2017-09-05	Fortgesetzt	H.C. Wainwright	Buy
2016-10-05	Bestätigt	H.C. Wainwright	Buy
2016-08-05	Herabstufung	Deutsche Bank	Hold → Sell
2016-03-11	Eingeleitet	Sidoti	Buy
2016-03-03	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten

Nov 16, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings - Yahoo Finance

Nov 16, 2024

Nov 14, 2024

Janus Henderson Group PLC Expands Stake in Ligand Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024

Ligand Pharmaceuticals to Present at Stifel 2024 Healthcare Conference | LGND Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Royal Bank of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat

Nov 12, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at Barclays - Defense World

Nov 12, 2024

Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Canada

Nov 12, 2024

Nov 11, 2024

LGND: 3Q Sales Surprise to the Upside - Zacks Small Cap Research

Nov 11, 2024

Lisanti Capital Growth LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Nov 11, 2024

Nov 09, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat

Nov 09, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Down 7.7%Should You Sell? - MarketBeat

Nov 09, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 09, 2024

Villere ST Denis J & Co. LLC Lowers Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Nov 09, 2024

Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast - Investing.com India

Nov 09, 2024

Nov 08, 2024

Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast By Investing.com - Investing.com Nigeria

Nov 08, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $150.00 at Barclays - MarketBeat

Nov 08, 2024

Oppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat

Nov 08, 2024

A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals - Benzinga

Nov 08, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Given Buy Rating at HC Wainwright - MarketBeat

Nov 08, 2024

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price - Yahoo Finance

Nov 08, 2024